EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Scorecard

Sources

Dose Diligence research deskSection 09 · Page 15 of 15Last updated 17 Nov 2026

Primary sources underpin the regulatory and product-programme statements. Supplier documentation describes published capabilities or terms, not independently audited service performance. URLs are provided below for the research record; inline citations identify their use.

  1. FDA — GLP-1 compounding policy clarification: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. Fifth Circuit — Tirzepatide delisting opinion, August 27, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  4. Fifth Circuit — Semaglutide delisting opinion, revised September 1, 2026: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  5. FDA — April 30, 2026 proposed 503B bulks-list exclusions: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  6. California Board of Pharmacy — New nonresident-pharmacy requirements: https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  7. FDA — DSCSA exemptions: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  8. FDA — November 9, 2026 GLP-1 safety-labeling communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  9. FDA — Human Drug Compounding Laws: https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
  10. FDA — Wholesale-distributor and third-party-logistics reporting: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  11. California Board of Pharmacy — Pharmacy/nonresident-pharmacy licensing: https://www.pharmacy.ca.gov/applicants/phy.shtml
  12. California Board of Pharmacy — Nonresident sterile-compounding application: https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  13. FDA — Registered Outsourcing Facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  14. FDA — Compounding inspections, recalls and other actions: https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  15. FDA — Form 483 frequently asked questions: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  16. ASHP — Guidelines on Outsourcing Sterile Compounding Services: https://www.ashp.org/-/media/assets/news-and-media/docs/ASHP-Guidelines-on-Outsourcing-Sterile-Compounding-Services.pdf
  17. FDA — Compounded injectable semaglutide dosing-error alert: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  18. HHS — Business Associates FAQs: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  19. HHS OIG — Fraud and Abuse Laws: https://www.oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
  20. LillyDirect — Patient FAQs: https://www.lilly.com/lillydirect/faq
  21. NovoCare — Provider home-delivery programme: https://www.novocare.com/hcp/delivery.html
  22. LillyDirect — Zepbound presentations and published terms: https://www.lilly.com/lillydirect/zepbound
  23. FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  24. Photon — Order Events documentation: https://docs.photon.health/docs/order-events
  25. Photon — Webhooks documentation: https://docs.photon.health/docs/webhooks
  26. ASHP — Outsourcing Sterile Products Vendor Assessment Tool: https://outsourcing.ashp.org/
  27. FDA — Compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  4. ca5.uscourts.gov · Source 4 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  5. fda.gov · Source 5 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  6. pharmacy.ca.gov · Source 6 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  7. fda.gov · Source 7 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  8. fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  9. fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  11. pharmacy.ca.gov · Source 11 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
  12. pharmacy.ca.gov · Source 12 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  13. fda.gov · Source 13 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  14. fda.gov · Source 14 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  15. fda.gov · Source 15 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  16. ashp.org · Source 16 ↗https://www.ashp.org/-/media/assets/news-and-media/docs/ASHP-Guidelines-on-Outsourcing-Sterile-Compounding-Services.pdf
  17. fda.gov · Source 17 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  18. hhs.gov · Source 18 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  19. oig.hhs.gov · Source 19 ↗https://www.oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
  20. lilly.com · Source 20 ↗https://www.lilly.com/lillydirect/faq
  21. novocare.com · Source 21 ↗https://www.novocare.com/hcp/delivery.html
  22. lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/zepbound
  23. fda.gov · Source 23 ↗https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  24. docs.photon.health · Source 24 ↗https://docs.photon.health/docs/order-events
  25. docs.photon.health · Source 25 ↗https://docs.photon.health/docs/webhooks
  26. outsourcing.ashp.org · Source 26 ↗https://outsourcing.ashp.org/
  27. fda.gov · Source 27 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Section sources →